A New Frontier in Refractory Pain: Non-Invasive Radioablation for Inflammatory Targets
A systematic review and meta-analysis published in *Heart* evaluates stereotactic arrhythmia radioablation (STAR), a novel non-invasive treatment using targeted radiation, for patients with refractory ventricular tachycardia. The analysis of 215 patients across 22 studies found that STAR significantly reduced ventricular tachycardia episodes by 81.5% and associated implantable cardioverter-defibrillator shocks by 84.7% over a mean follow-up of nearly 12 months. While offering substantial symptomatic relief, the treatment showed a high recurrence rate, with only 23.1% of patients remaining VT-free. The safety profile revealed a notable incidence of severe adverse events, though most were not directly attributed to the STAR procedure itself, highlighting an area for protocol refinement in this emerging therapeutic approach.
Study Significance: For rheumatology, this research on targeted non-invasive ablation presents a conceptual bridge for managing refractory inflammatory foci, such as persistent synovitis or enthesitis. The methodology underscores the potential of precision radiation to modulate hyperactive tissue, a strategy that could be adapted for localized, treatment-resistant manifestations of autoimmune diseases. It prompts consideration of how interdisciplinary techniques from cardiology might inform future approaches to severe, localized chronic pain and inflammation unresponsive to conventional biologic therapies or DMARDs.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
